From Acera Surgical and Telos Medical’s partnership to Xtant Medical’s 510(k) clearance, here are seven medtech stories we missed this week but thought were still worth a mention. 1. Acera Surgical partners with Telos Medical for Restrata wound matrix trial Telos Partners announced in a Sept. 14 press release that Acera Surgical has chosen Telos to […]
Clinical Trials
Sanofi touts patient-driven dose titration of Toujeo insulin glargine injection
Sanofi (NYSE:SNY) today touted data from the Take Control trial of its Toujeo insulin glargine product in patients with Type II diabetes. The study compared patients using Toujeo with a titration algorithm managed by the patient, compared to patients whose dose adjustment was decided by their physicians. The 631-patient trial revealed that after six months, patients […]
KemPharm tackles pediatric ADHD using ligand-activated drug
Travis Mickle’s work developing better drugs for attention deficit hyperactivity disorder is deeply personal – he has ADHD and so do his children. After receiving his PhD in organic chemistry from the University of Iowa, Mickle went on to work at New River Pharmaceuticals, where he developed the leading treatment for ADHD, Vyvanse. Now he […]
Sanofi’s Toujeo beats Lantus at stabilizing blood sugar in T2D patients
Adults with Type II diabetes treated with Sanofi‘s (NYSE:SNY) Toujeo Gla-300 insulin glargine had better blood glucose stability than those treated with the company’s Lantus Gla-100 insulin glargine product, according to a study presented at the annual meeting of the European Association for the Study of Diabetes. The analysis re-analyzed patient data from the Edition […]
Insulet touts real-world data for Omnipod insulin management tech
Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes. The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data […]
VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) touted data for its In.Pact Admiral drug-coated balloon this week at the Vascular Interventional Advances (VIVA) 2017 conference. The company presented two-year, real-world data from the In.Pact Global study, as well as four-year results from the pivotal In.Pact SFA study. Data from the In.Pact Global study showed a 83.3% rate of freedom from clinically-driven target […]
Fractyl Labs touts 1-year data for Revita DMR in T2D patients
Fractyl Laboratories touted data today showing sustained improvement in glycemic parameters after one year following a single treatment with its Revita duodenal mucosal resurfacing system in patients with Type II diabetes. “This is the first presentation of one-year data on the durability of the Revita DMR procedure in Type II diabetes. The Revita DMR procedure […]
Novartis partners with nonprofit for novel malaria drug
David Hughes and his team at Novartis (NYSE:NVS) have screened nearly a million compounds to find a few to specifically target the drug-resistant plasmodium parasite that causes malaria. This technique – of throwing hundreds of thousands of drugs through a variety of high-throughput tests and hoping to find the ones that perform well – is common […]
Boehringer Ingelheim’s Jardiance cuts risk of cardiovascular death in T2D patients
Boehringer Ingelheim and Eli Lilly (NYSE:LLY) touted post-hoc analyses today showing that Jardiance reduced the risk of cardiovascular death in people with Type II diabetes and established cardiovascular disease, independent of blood sugar control at the start of the study. The companies also reported a reduced risk in cardiovascular death when Jardiance was added to first […]
Study: Sanofi’s diabetes drug brings earlier blood sugar control than insulin glargine
A post-hoc analysis of two late-stage trials of Sanofi‘s (NYSE:SNY) Soliqua insulin glargine and lixisenatide injection showed that it provides blood sugar control earlier and in more adults than just insulin glargine, the company reported. The analysis was presented today at the European Association for the Study of Diabetes in Portugal. Researchers reviewed data from […]